Secondary prevention in thrombotic antiphospholipid syndrome

被引：11

作者：

Pengo, V. ^{[1
]}

Denas, G. ^{[1
]}

Banzato, A. ^{[1
]}

Bison, E. ^{[1
]}

Bracco, A. ^{[1
]}

Facchinetti, M. ^{[2
]}

Hoxha, A. ^{[2
]}

Ruffatti, A. ^{[2
]}

机构：

[1] Univ Padua, Thrombosis Ctr, Dept Cardiac Thorac & Vasc Sci, I-35128 Padua, Italy

[2] Univ Padua, Rheumatol Unit, Dept Med, I-35128 Padua, Italy

来源：

LUPUS | 2012年 / 21卷 / 07期

关键词：

antiphospholipid; prevention; drugs; thrombosis; RECURRENT THROMBOSIS; THERAPY; INTENSITY; WARFARIN; RISK;

D O I：

10.1177/0961203312444773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Secondary prevention of venous thromboembolism in antiphospholipid syndrome (APS) is usually made using vitamin K antagonists (VKAs) to maintain an international normalized ratio (INR) between 2.0 and 3.0. The optimal intensity of anticoagulation was determined in two prospective randomized controlled trials, both excluding the benefit of more intense anticoagulation. The same regimen is also recommended in patients with APS and arterial thromboembolism as aspirin does not appear to protect against recurrences. The duration of treatment is usually indefinite because of a substantial risk of recurrence. Lupus (2012) 21, 734-735.

引用

页码：734 / 735

页数：2

共 50 条

[41] OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?
Morales, R. Serrano
Nieto, R.
Porta, S.
Roberts, K.
Lema, L.
Maldini, C.
Tissera, Y.
Albiero, J. A.
Savio, V.
Goizueta, C.
Lobo, V.
Broll, A.
Cucchiaro, N.
Perez, S.
Izaguirre, P.
Estevez, A.
Abalo, A. I.
Etcheverry, M.
Bellomio, V. I.
Leguizamon, M. L.
Antoniol, N.
Perandones, C.
Pisoni, C.
De la Torre, M. L.
Garcia, M.
Velloso, M. S.
Sacnun, M.
Gobbi, C.
Guaglione, D.
Vivero, F.
Saurit, V.
Benzaquen, N.
Nemman, V.
Remondino, G.
Escobar, M. Machado
Scolnik, M.
Danielsen, C.
Gomez, G.
Babini, A. M.
Brigante, A.
Luissi, A.
Coello, V. V. Castro
Sorrentino, L.
Berman, H.
Alba, P.
Pons-Estel, G.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1196 - 1196
[42] Chronic thrombotic microangiopathy secondary to antiphospholipid syndrome, presenting with severe hypertension and chronic renal impairment
Yee, Yucai
Angkodjojo, Stanley
Tan, Puay Hoon
BMJ CASE REPORTS, 2019, 12 (09)
[43] Thrombotic and non-thrombotic neurological manifestations in Primary Antiphospholipid Syndrome
Cunha, C.
Serodio, J.
Moreira, I.
Bettencourt, A.
Santos, E.
Samoes, R.
Carvalheiras, G.
Cavaco, S.
Martins Silva, A.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 37 - 37
[44] PREVENTION OF MISCARRIAGE IN ANTIPHOSPHOLIPID SYNDROME
PASSALEVA, A
MASSAI, G
DELIOS, MM
LIVI, C
ABBATE, R
AUTOIMMUNITY, 1992, 14 (02) : 121 - 125
[45] Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People With Antiphospholipid Syndrome
Bala, Malgorzata M.
Celinska-Lowenhoff, Magdalena
Szot, Wojciech
Padjas, Agnieszka
Kaczmarczyk, Mateusz
Swierz, Mateusz J.
Undas, Anetta
STROKE, 2018, 49 (03) : E41 - E42
[46] Prevention of thrombosis in antiphospholipid syndrome
Lim, Wendy
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 707 - 713
[47] Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events Following Acute Coronary Syndrome
Tsang, Katrina
Hartmark-Hill, Jennifer R.
AMERICAN FAMILY PHYSICIAN, 2013, 88 (12) : 821 - 822
[48] Prasugrel for Secondary Prevention of Thrombotic Stroke
Yagita, Yoshiki
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2023, 30 (03) : 220 - 221
[49] Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome
Anunciacion-Llunell, Ariadna
Munoz, Candido
Roggenbuck, Dirk
Frasca, Stefano
Pardos-Gea, Josep
Esteve-Valverde, Enrique
Alijotas-Reig, Jaume
Miro-Mur, Francesc
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
[50] Thrombotic antiphospholipid syndrome: From guidelines to clinical management
Paredes-Ruiz, Diana
Martin-Iglesias, Daniel
Ruiz-Irastorza, Guillermo
MEDICINA CLINICA, 2024, 163 : S22 - S30

← 1 2 3 4 5 →